Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06140836 · ClinicalTrials.gov registry record · Phase 3
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
- 20
- Study locations
NCT06140836 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 190 participants, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06140836, a Phase 3 study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Crizotinib
- DRUG Repotrectinib
Study Locations (20)
Other
- Local Institution - 0106 - Buenos Aires
- Local Institution - 0207 - Buenos Aires
- Local Institution - 0093 - Córdoba
- Local Institution - 0041 - Vienna
São Paulo
- Local Institution - 0029 - Barretos
- Local Institution - 0037 - São José do Rio Preto
- Local Institution - 0209 - São Paulo
- Local Institution - 0147 - São Paulo
Massachusetts
- Local Institution - 0075 - Boston
- Local Institution - 0201 - Boston
New York
- Local Institution - 0210 - Mineola
- Local Institution - 0134 - New York
Buenos Aires
- Local Institution - 0092 - Ciudad Autónoma de Buenos Aires
- Instituto Alexander Fleming - Ciudad Autónoma de Buenos Aires
Rio Grande do Sul
- Local Institution - 0033 - Porto Alegre
- Local Institution - 0034 - Porto Alegre
Iowa
- Local Institution - 0221 - Des Moines
Washington
- Local Institution - 0214 - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2023-12-21 |
| Est. Completion | 2027-03-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06140836
The ClinicalTrials.gov registry entry for NCT06140836 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (41% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which Crizotinib is the first listed.
NCT06140836 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, São Paulo, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06140836 about?
NCT06140836 is a clinical study titled "A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)". The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).
What is the current status of trial NCT06140836?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2023-12-21. Estimated completion is 2027-03-15.
What conditions does trial NCT06140836 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT06140836?
The interventions under investigation include: Crizotinib (DRUG), Repotrectinib (DRUG).
Who is sponsoring clinical trial NCT06140836?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06140836 being conducted?
This trial has 20 study locations across Iowa, Massachusetts, New York, Washington, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.